William H. Carson, M.D., president and CEO for Otsuka Pharmaceutical Development & Commercialization, Inc., explains the reasons behind the company’s newest endeavors.
Biopharma leaders need to weigh carefully the short-term gains versus long-term impact on a company’s overall reputation that price hikes can have when placed under the powerful lens of the social media microscope.
Six years after the enactment of the Affordable Care Act (ACA), policymakers are just beginning to appreciate a little-known provision that essentially outsources Congress’ authority over Medicare to the executive branch.
John Crowley, chairman and CEO of Amicus Therapeutics discusses why biotechs in the rare disease space face particularly unique and fundamental challenges.
It can be tough to move quickly when you have a big organization; all these processes and procedures are in place to keep everything running as consistently and predictably as possible. That being said, it is amazing how fast J&J has changed and how fast they can make decisions now because of this new structure.
Dr. Leah Makley, president and CSO, founded ViewPoint based on five years of research she conducted in the lab of cofounder Dr. Jason Gestwicki, where all work is dedicated to protein misfolding, primarily in neurodegenerative diseases such as Alzheimer’s.
As a company that is moving forward with mobile technology adoption, I can tell you that regulators are probably the least of our concerns,” says Rob DiCicco, VP, clinical innovation and digital platforms at GSK.
There is an ecosystem of many stakeholders who play a role in the discovery of new drugs, and each of them have a vested interest in making the drug discovery system work successfully and efficiently.
Although pharma has been active in social media for some time, the industry is still in the relatively early stages of social media maturity. The findings of a recent survey conducted by C3i Healthcare Connections, a Telerx company, confirmed this point.
When life sciences and healthcare organizations look at their medication compliance numbers, they often feel like a baseball manager with a slumping hitter. The data shows that the hitter is 0 for 22, with 10 strikeouts, over the last few games. But it offers little guidance on why the player doesn’t appear to be able to hit water if he fell out of a boat or what the manager can do to get to the hitter back on track again.
Data is exponentially increasing while habits remain steeped in legacy systems and the past when it comes to safety and pharmacovigilance (PV) in the pharmaceutical ecosystem.
About 50 percent of all Phase III trials fail. That is an expensive problem for the pharmaceutical industry, as a 2014 study by the U.S. Department of Health and Human Services estimated the average cost of a Phase III trial to be $20 million.
Prior to my interview with William H. Carson, M.D., I noted that the president and CEO for Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) matriculated at Harvard University. I was curious as to how Dr. Carson came to be enrolled at the institution. “Do you want the short story or long story?” he laughs.
Following Luc Debruyne’s participation in an educational session at this year’s BIO International Convention, the president of GSK Vaccines sat down with me to share his insights on the world of vaccines. During our conversation, (much of which was captured in the September 2016 feature article in Life Science Leader magazine), I asked Debruyne about some of the challenges faced by vaccine developers when it comes to viruses like Ebola and Zika.
Not long ago, a research team from the CDC fleshed out the measles activity in the United States. Much of the recent measles outbreak was linked to international travel and Disney Theme parks. While the threat may have come from imported infections, the reason the measles threat became a reality was largely the result of unvaccinated Americans. According to Luc Debruyne, president of GSK Vaccines and the subject of a feature article in Life Science Leader magazine’s September 2016 issue, the anti-vaccination movement is actually referred to as vaccine hesitancy, and is not just a U.S. but global phenomenon.
Author Steven Covey’s famous phrase, “To Live, To Love, To Learn, To Leave a Legacy” is what popped into my head while attending the Community of Hope’s Annual Dinner Auction as the invited guest of pharmaceutical industry icon, Fred Hassan. Twenty years ago Hassan founded this annual charity event that brings together two communities (i.e., social services and the biopharmaceutical industry) to do good in their own backyard (i.e., New Jersey and Pennsylvania). In his evening remarks to this year’s nearly 1,000 attendees, he explained that he created the event as a way of “supercharging” the Community of Hope’s fundraising efforts to help area homeless (including veterans).
Life Science Leader magazine was recently invited to attend The Economist’s War On Cancer healthcare forum in Boston, Sept. 28, 2016. Though all of the day’s sessions were intriguing, the one that got me up out of my chair to track down a speaker before his exit occurred at 4 p.m. Entitled, “Going Global – Examples Of Cancer Advances From Around The World,” the first person to speak was Kelvin Lee, M.D., immunology chairman from the Roswell Park Cancer Institute. Dr. Lee says that his experience in working with Cuba began quite by accident in 2011.